(CercleFinance.com) – In a letter addressed to shareholders, Stéphane Bancel, the director of Moderna, believes that the most optimistic five-year scenario established in 2018 is being realized.
“As we reflect on the past year, our commitment to leveraging mRNA to deliver transformative medicines to patients has never been stronger,” says the executive, who says he has the platform, technology, resources and team needed to establish ‘a new era of medicine’.
At the same time, the laboratory indicates that it is preparing for the potential launch of its experimental vaccine against respiratory syncytial virus (RSV) in 2024.
‘Our objective for 2024 and 2025 is to stimulate sales growth and profitability,’ continues the manager. Stéphane Bancel also plans to double the number of phase 3 programs by 2025 and launch up to 15 products in five years.
‘We expect to break even in 2026, as revenues increase and late-stage R&D costs decrease, when current large Phase 3 clinical trials end and give rise to many potential launches new products’, he concluded.
Following this announcement, the stock soared by more than 13% in New York.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Are you following this action?
Receive all the information on Moderna in real time: